Multi-target enzyme inhibitor
The active ingredient group of multi-target enzyme inhibitors is a new classification of drugs , which through their structure cause an inhibition of several enzymes at the same time and thus prevent several metabolic processes in parallel, whereby it can be assumed that this broad effect is desired. These drugs are used in the suppression or treatment of tumors in oncology . This procedure is necessary because several key enzymes are often involved in the process of tumor growth and spread, which must be blocked as comprehensively as possible for treatment.
The interesting thing about this is the procedure for drug development, which contradicts the classic drug development, since it aims at the highest possible selectivity on a target structure in order to limit or prevent possible side effects and interactions.
Medicinal substances
The first representative of this group, for which the group name was also coined by the manufacturer Lilly , is the drug pemetrexed (Alimta ® ), which is used to treat non-small cell lung cancer (NSCLC) and inoperable malignant pleural mesothelioma (MPM).
The two substances Lapatinib (Tykerb ® and Tyverb ® ) (dual tyrosine kinase inhibitor ) and pazopanib (multi-target tyrosine kinase inhibitor) from the manufacturer GlaxoSmithKline , which are currently being used together as a combination in a phase- II study for the treatment of cervical cancer .
Individual evidence
- ↑ pta-aktuell.de: Arzneimittel-Telegram Archive 2004 ( Memento of the original from August 16, 2010 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice.
- ↑ Information page of the Lilly company
- ↑ onkologie-telegramm.de: The therapy of NSCLC ( page no longer available , search in web archives ) Info: The link was automatically marked as defective. Please check the link according to the instructions and then remove this notice. (PDF; 80 kB).
- ↑ bionity.com: Information page on the phase II study
